J Clin Invest. 2024 Oct 15;134(20):e172882. doi: 10.1172/JCI172882.
Substance use disorders (SUDs) are highly prevalent and associated with excess morbidity, mortality, and economic costs. Thus, there is considerable interest in the early identification of individuals who may be more susceptible to developing SUDs and in improving personalized treatment decisions for those who have SUDs. SUDs are known to be influenced by both genetic and environmental factors. Polygenic scores (PGSs) provide a single measure of genetic liability that could be used as a biomarker in predicting disease development, progression, and treatment response. Although PGSs are rapidly being integrated into clinical practice, there is little information to guide clinicians in their responsible use and interpretation. In this Review, we discuss the potential benefits and pitfalls of the use of PGSs in the clinical care of SUDs, highlighting current research. We also provide suggestions for important considerations prior to implementing the clinical use of PGSs and recommend future directions for research.
物质使用障碍（SUD）的发病率很高，与过多的发病率、死亡率和经济成本有关。因此，人们对早期识别可能更容易患上 SUD 的个体以及改善患有 SUD 的个体的个性化治疗决策非常感兴趣。SUD 已知受到遗传和环境因素的影响。多基因评分（PGS）提供了一种衡量遗传易感性的单一指标，可以用作预测疾病发展、进展和治疗反应的生物标志物。尽管 PGS 正在迅速融入临床实践，但几乎没有信息可以指导临床医生负责任地使用和解释它们。在这篇综述中，我们讨论了在 SUD 的临床护理中使用 PGS 的潜在益处和陷阱，强调了当前的研究。我们还就实施 PGS 的临床使用之前需要考虑的重要事项提出了建议，并为研究的未来方向提出了建议。
